

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10859246/publications.pdf>

Version: 2024-02-01

14
papers

1,249
citations

759055

12
h-index

1058333

14
g-index

14
all docs

14
docs citations

14
times ranked

1762
citing authors

#	ARTICLE	IF	CITATIONS
1	Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1295-1302.	0.5	275
2	Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2007, 26, 1495-1498.	1.0	192
3	Serum and Urinary Cell-free MiR-146a and MiR-155 in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 2516-2522.	1.0	174
4	Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: Association with human papillomavirus infection. <i>Arthritis and Rheumatism</i> , 2004, 50, 3619-3625.	6.7	145
5	Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. <i>Scandinavian Journal of Rheumatology</i> , 2002, 31, 296-300.	0.6	117
6	Glomerular and tubulointerstitial miR-638, miR-198 and miR-146a expression in lupus nephritis. <i>Nephrology</i> , 2012, 17, 346-351.	0.7	99
7	Natural History of Cervical Papilloma Virus Infection in Systemic Lupus Erythematosus – A Prospective Cohort Study. <i>Journal of Rheumatology</i> , 2010, 37, 330-340.	1.0	71
8	Immunopathological Roles of Cytokines, Chemokines, Signaling Molecules, and Pattern-Recognition Receptors in Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-14.	3.3	56
9	Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. <i>Translational Research</i> , 2016, 167, 138-151.	2.2	34
10	Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: A prospective cohort study. <i>Arthritis Care and Research</i> , 2011, 63, 269-276.	1.5	32
11	Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2012, 14, R80.	1.6	28
12	Down-Regulated NOD2 by Immunosuppressants in Peripheral Blood Cells in Patients with SLE Reduces the Muramyl Dipeptide-Induced IL-10 Production. <i>PLoS ONE</i> , 2011, 6, e23855.	1.1	19
13	Urinary mRNA in Systemic Lupus Erythematosus. <i>Advances in Clinical Chemistry</i> , 2013, 62, 197-219.	1.8	4
14	Correspondence on “No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related “physician-reported spondylitis””. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e187-e187.	0.5	3